Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
OBJECTIVE
High cumulative epipodophyllotoxin dosages are reported to be associated with an elevated risk for secondary acute myeloid leukemia (s-AML). This study examined the risk of s-AML following cumulative etoposide doses greater than 2 g/m2 in patients with metastatic germ cell tumors (GCT).


METHODS
The incidence of s-AML was retrospectively assessed in patients treated within clinical trials between January 1986 and February 1996 at four university centers. All patients received high-dose chemotherapy (HDCT) plus autologous stem-cell support for metastatic GCT, including high cumulative etoposide doses (> 2 g/m2). Minimum patient follow-up was 12 months. Standardized morbidity ratio (SMR) was calculated to estimate the risk associated with high cumulative etoposide doses, as compared with the general population.


RESULTS
A total of 302 patients with a median age of 29 years (range, 15 to 55) received a median cumulative etoposide dose of 5 g/m2 (range, 2.4 to 14 g/m2). Four cases of s-AML were observed, which resulted in a cumulative incidence of 1.3% (95% confidence interval [CI], 0.38% to 3.59%) at 52 months of median follow-up (range, 12 to 198). Two cases of secondary myelodysplasia (s-MDS) developed in patients with primary mediastinal GCT. Based on the observed four cases of AML, which are most likely etoposide-related, the risk for developing s-AML (SMR, 160 [95% CI, 43.7 to 411.2]) is significantly increased in comparison to the age-matched general population.


CONCLUSIONS
Due to the low incidence of AML in the general population, the significantly elevated risk for developing s-AML affects only 1.3% of all patients who receive etoposide doses greater than 2 g/m2. HDCT, including etoposide doses greater than 2 g/m2, is associated with an acceptably low incidence of s-AML in patients with advanced GCT.
Kollmannsberger
C
C
Department of Hematology/Oncology, University of Tuebingen Medical Center, Germany.
Beyer
J
J
Droz
J P
JP
Harstrick
A
A
Hartmann
J T
JT
Biron
P
P
Fléchon
A
A
Schöffski
P
P
Kuczyk
M
M
Schmoll
H J
HJ
Kanz
L
L
Bokemeyer
C
C
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D018237:Germinoma / Q000188:drug therapy* / Q000556:secondary; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000139:chemically induced; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide